585 related articles for article (PubMed ID: 30260273)
21. Early symptomatic improvements as a predictor of response to repeated-dose intravenous ketamine: Results from the Canadian Rapid Treatment Center of Excellence.
Lipsitz O; McIntyre RS; Rodrigues NB; Kaster TS; Cha DS; Brietzke E; Gill H; Nasri F; Lin K; Subramaniapillai M; Kratiuk K; Teopiz K; Lui LMW; Lee Y; Ho R; Shekotikhina M; Mansur RB; Rosenblat JD
Prog Neuropsychopharmacol Biol Psychiatry; 2021 Mar; 105():110126. PubMed ID: 33031861
[TBL] [Abstract][Full Text] [Related]
22. Ketamine for the treatment of depression.
Howland RH
J Psychosoc Nurs Ment Health Serv; 2013 Jan; 51(1):11-4. PubMed ID: 23413455
[TBL] [Abstract][Full Text] [Related]
23. Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression.
Murrough JW; Perez AM; Pillemer S; Stern J; Parides MK; aan het Rot M; Collins KA; Mathew SJ; Charney DS; Iosifescu DV
Biol Psychiatry; 2013 Aug; 74(4):250-6. PubMed ID: 22840761
[TBL] [Abstract][Full Text] [Related]
24. Working memory associated with anti-suicidal ideation effect of repeated-dose intravenous ketamine in depressed patients.
Chen X; Wang M; Hu Y; Zhan Y; Zhou Y; Zheng W; Liu W; Wang C; Zhong X; Li H; Lan X; Ning Y; Zhang B
Eur Arch Psychiatry Clin Neurosci; 2021 Apr; 271(3):431-438. PubMed ID: 33386430
[TBL] [Abstract][Full Text] [Related]
25. Intravenous arketamine for treatment-resistant depression: open-label pilot study.
Leal GC; Bandeira ID; Correia-Melo FS; Telles M; Mello RP; Vieira F; Lima CS; Jesus-Nunes AP; Guerreiro-Costa LNF; Marback RF; Caliman-Fontes AT; Marques BLS; Bezerra MLO; Dias-Neto AL; Silva SS; Sampaio AS; Sanacora G; Turecki G; Loo C; Lacerda ALT; Quarantini LC
Eur Arch Psychiatry Clin Neurosci; 2021 Apr; 271(3):577-582. PubMed ID: 32078034
[TBL] [Abstract][Full Text] [Related]
26. Antidepressant effect of repeated ketamine administration on kynurenine pathway metabolites in patients with unipolar and bipolar depression.
Zhou Y; Zheng W; Liu W; Wang C; Zhan Y; Li H; Chen L; Li M; Ning Y
Brain Behav Immun; 2018 Nov; 74():205-212. PubMed ID: 30213652
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and Safety of a Rapid Intravenous Injection of Ketamine 0.5 mg/kg in Treatment-Resistant Major Depression: An Open 4-Week Longitudinal Study.
Vidal S; Gex-Fabry M; Bancila V; Michalopoulos G; Warrot D; Jermann F; Dayer A; Sterpenich V; Schwartz S; Vutskits L; Khan N; Aubry JM; Kosel M
J Clin Psychopharmacol; 2018 Dec; 38(6):590-597. PubMed ID: 30346333
[TBL] [Abstract][Full Text] [Related]
28. Augmentation of response and remission to serial intravenous subanesthetic ketamine in treatment resistant depression.
Shiroma PR; Johns B; Kuskowski M; Wels J; Thuras P; Albott CS; Lim KO
J Affect Disord; 2014 Feb; 155():123-9. PubMed ID: 24268616
[TBL] [Abstract][Full Text] [Related]
29. Efficacy, Safety, and Durability of Repeated Ketamine Infusions for Comorbid Posttraumatic Stress Disorder and Treatment-Resistant Depression.
Albott CS; Lim KO; Forbes MK; Erbes C; Tye SJ; Grabowski JG; Thuras P; Batres-Y-Carr TM; Wels J; Shiroma PR
J Clin Psychiatry; 2018; 79(3):. PubMed ID: 29727073
[TBL] [Abstract][Full Text] [Related]
30. Clinical outcomes in the biomarkers of ketamine (Bio-K) study of open-label IV ketamine for refractory depression.
Parikh SV; Vande Voort JL; Yocum AK; Achtyes E; Goes FS; Nykamp L; Singh B; Lopez-Vives D; Sera CE; Maixner D; Tarnal V; Severe J; Bartek S; Tye SJ; Rico J; Stoppel CJ; Becerra A; Smart L; Miller CR; Frye MA; Greden JF; Bobo WV
J Affect Disord; 2024 Mar; 348():143-151. PubMed ID: 38142892
[TBL] [Abstract][Full Text] [Related]
31. Is Ketamine the Future Clozapine for Depression? A Case Series and Literature Review on Maintenance Ketamine in Treatment-resistant Depression With Suicidal Behavior.
Chan LF; Eu CL; Soh SY; Maniam T; Shahidii Kadir Z; Chong BTW; Loo JL; Sharip S; Wong VCW; Loo TH; Ng YP; Kahn DA
J Psychiatr Pract; 2018 Jul; 24(4):279-291. PubMed ID: 30427812
[TBL] [Abstract][Full Text] [Related]
32. Intravenous ketamine infusion for a patient with treatment-resistant major depression: a 10-month follow-up.
Kwon JH; Sim WS; Hong JP; Song IS; Lee JY
J Clin Pharm Ther; 2018 Aug; 43(4):581-583. PubMed ID: 29372569
[TBL] [Abstract][Full Text] [Related]
33. Effect of baseline anxious depression on initial and sustained antidepressant response to ketamine.
Ionescu DF; Luckenbaugh DA; Niciu MJ; Richards EM; Slonena EE; Vande Voort JL; Brutsche NE; Zarate CA
J Clin Psychiatry; 2014 Sep; 75(9):e932-8. PubMed ID: 25295436
[TBL] [Abstract][Full Text] [Related]
34. Baseline insomnia as a predictor of antidepressant efficacy to repeated intravenous ketamine for unipolar and bipolar depression: A preliminary study.
Liu W; Zhou Y; Wang C; Zheng W; Zhan Y; Lan X; Zhang B; Li H; Chen L; Li M; Ning Y
J Affect Disord; 2020 Jun; 271():1-8. PubMed ID: 32312692
[TBL] [Abstract][Full Text] [Related]
35. A 12-month naturalistic observation of three patients receiving repeat intravenous ketamine infusions for their treatment-resistant depression.
Szymkowicz SM; Finnegan N; Dale RM
J Affect Disord; 2013 May; 147(1-3):416-20. PubMed ID: 23182590
[TBL] [Abstract][Full Text] [Related]
36. Real-world effectiveness of repeated ketamine infusions for treatment-resistant bipolar depression.
Fancy F; Rodrigues NB; Di Vincenzo JD; Chau EH; Sethi R; Husain MI; Gill H; Tabassum A; Mckenzie A; Phan L; McIntyre RS; Rosenblat JD
Bipolar Disord; 2023 Mar; 25(2):99-109. PubMed ID: 36516343
[TBL] [Abstract][Full Text] [Related]
37. Long-term outcomes of repeated ketamine infusions in patients with unipolar and bipolar depression: A naturalistic follow-up study.
Li W; Zhou Y; Liu W; Wang C; Lan X; Zhang Z; Zhang F; Ye Y; Liu H; Wu K; McIntyre RS; Ning Y
J Affect Disord; 2022 Mar; 300():172-178. PubMed ID: 34952122
[TBL] [Abstract][Full Text] [Related]
38. Rapid effectiveness of intravenous ketamine for ultraresistant depression in a clinical setting and evidence for baseline anhedonia and bipolarity as clinical predictors of effectiveness.
Thomas RK; Baker G; Lind J; Dursun S
J Psychopharmacol; 2018 Oct; 32(10):1110-1117. PubMed ID: 30182797
[TBL] [Abstract][Full Text] [Related]
39. The Concurrent Treatment With Intravenous Ketamine and an Irreversible Monoamine Oxidase Inhibitor for Treatment-Resistant Depression Without Hypertensive Crises.
Wang JCC; Swainson J
J Clin Psychopharmacol; 2020; 40(5):515-517. PubMed ID: 32740556
[No Abstract] [Full Text] [Related]
40. A preliminary study of anti-suicidal efficacy of repeated ketamine infusions in depression with suicidal ideation.
Zhan Y; Zhang B; Zhou Y; Zheng W; Liu W; Wang C; Li H; Chen L; Yu L; Walter M; Li M; Li MD; Ning Y
J Affect Disord; 2019 May; 251():205-212. PubMed ID: 30927581
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
